arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Immunovant, Inc.

IMVT
$39.96 ▲ +0.19 (+0.48%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
33 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunovant, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share None
Trailing P/E
Price / Book 9.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

33-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-147.86M
↓ -38.9%
FCF / Share Free cash flow per share
$-0.51
↑ +13.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 33 quarters